{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:15:36Z","timestamp":1778040936577,"version":"3.51.4"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>\n                    Gastrointestinal (GI) disease complicates anticoagulation by simultaneously increasing bleeding risk and maintaining high thromboembolic vulnerability. Mucosal injury, portal hypertension, malignancy, inflammatory bowel disease, and vascular lesions predispose to hemorrhage, whereas interruption of therapy increases the risk of stroke, venous thromboembolism, and stent thrombosis. Contemporary management follows an indication-first, risk-balanced approach that integrates thrombotic urgency, GI disease phenotype, and patient-specific bleeding-risk factors. Direct oral anticoagulants demonstrate heterogeneous GI bleeding profiles, with higher risk observed with dabigatran and rivaroxaban, while apixaban is comparatively safer in high-risk populations. Periprocedural management is guided by procedural bleeding risk, renal function, and drug pharmacokinetics, with strategies emphasizing appropriate interruption and minimal use of bridging. In acute GI bleeding, management prioritizes hemodynamic stabilization, restrictive transfusion strategies, and early endoscopic or interventional radiology\u2013guided source control, with selective use of reversal agents in severe cases. Adjunctive measures, including proton pump inhibitor therapy and\n                    <jats:italic toggle=\"yes\">Helicobacter pylori<\/jats:italic>\n                    eradication, reduce recurrent bleeding risk. Resumption of anticoagulation is generally associated with improved survival and reduced thromboembolic events when timed appropriately. Key knowledge gaps remain regarding optimal reversal strategies, lesion-specific restart timing, and management in cirrhotic populations.\n                  <\/jats:p>","DOI":"10.1097\/crd.0000000000001301","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:00:38Z","timestamp":1778040038000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Anticoagulation in Patients With Gastrointestinal Disease"],"prefix":"10.1097","author":[{"given":"Omar","family":"Alkasabrah","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaishkar","family":"Ramesh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Texila American University, Guyana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhe Kinner","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Qasim","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faiza Aman","family":"Jajja","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"R1-20260506","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ajg.2014.398","article-title":"The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.","volume":"110","author":"Sengupta","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R2-20260506","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archinternmed.2012.4261","article-title":"Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding.","volume":"172","author":"Witt","year":"2012","journal-title":"Arch Intern Med"},{"key":"R3-20260506","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.gie.2015.09.035","article-title":"The management of antithrombotic agents for patients undergoing GI endoscopy.","volume":"83","author":"Acosta","year":"2016","journal-title":"Gastrointest Endosc"},{"key":"R4-20260506","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/gastroent16040041","article-title":"Management of antithrombotic therapy in acute gastrointestinal bleeding.","volume":"16","author":"Papantoniou","year":"2025","journal-title":"Gastroenterol Insights"},{"key":"R5-20260506","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jcag\/gwac010","article-title":"American College of Gastroenterology-Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period.","volume":"5","author":"Abraham","year":"2022","journal-title":"J Can Assoc Gastroenterol"},{"key":"R6-20260506","doi-asserted-by":"crossref","first-page":"1049283","DOI":"10.3389\/fphar.2022.1049283","article-title":"Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: an updated traditional and Bayesian network meta-analysis.","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"R7-20260506","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"R8-20260506","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S2468-1253(16)30162-5","article-title":"Risk of gastrointestinal bleeding with direct oral anticoagulants: a systematic review and network meta-analysis.","volume":"2","author":"Burr","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R9-20260506","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/gutjnl-2021-325184","article-title":"Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update.","volume":"70","author":"Veitch","year":"2021","journal-title":"Gut"},{"key":"R10-20260506","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jvir.2019.04.017","article-title":"Society of interventional radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions\u2014part II: recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe.","volume":"30","author":"Patel","year":"2019","journal-title":"J Vasc Interv Radiol"},{"key":"R11-20260506","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1211801","article-title":"Transfusion strategies for acute upper gastrointestinal bleeding.","volume":"368","author":"Villanueva","year":"2013","journal-title":"N Engl J Med"},{"key":"R12-20260506","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1055\/s-0034-1365235","article-title":"Embolization versus surgery for peptic ulcer bleeding after failed endoscopic hemostasis: a meta-analysis.","volume":"2","author":"Kyaw","year":"2014","journal-title":"Endosc Int Open"},{"key":"R13-20260506","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjcard.2026.01.006","article-title":"Effectiveness and safety of apixaban versus warfarin in atrial fibrillation patients with malignancy: a propensity-matched analysis.","volume":"264","author":"Agrawal","year":"2026","journal-title":"Am J Cardiol"},{"key":"R14-20260506","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.amjcard.2026.02.006","article-title":"Impact of frailty on outcomes following percutaneous left atrial appendage occlusion: a propensity-score matched analysis.","volume":"265","author":"Jain","year":"2026","journal-title":"Am J Cardiol"},{"key":"R15-20260506","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJM200103293441304","article-title":"Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.","volume":"344","author":"Chan","year":"2001","journal-title":"N Engl J Med"},{"key":"R16-20260506","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1001\/jama.2018.17242","article-title":"Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding.","volume":"320","author":"Ray","year":"2018","journal-title":"JAMA"},{"key":"R17-20260506","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cgh.2023.12.022","article-title":"Reduction of upper gastrointestinal bleeding risk with proton pump inhibitor therapy in Asian patients with atrial fibrillation receiving direct oral anticoagulant: a nationwide population-based cohort study.","volume":"22","author":"Lee","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R18-20260506","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1097\/HEP.0000000000000647","article-title":"AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis.","volume":"79","author":"Kaplan","year":"2024","journal-title":"Hepatology"},{"key":"R19-20260506","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/HEP.0000000000000530","article-title":"AASLD Practice Guidance on the use of TIPS, variceal embolization, and retrograde transvenous obliteration in the management of variceal hemorrhage.","volume":"79","author":"Lee","year":"2024","journal-title":"Hepatology"},{"key":"R20-20260506","article-title":"Statins and the cardio-hepatic axis: balancing cardiovascular protection with liver disease safety [published online ahead of print November 8, 2025].","author":"Alkasabrah","journal-title":"Cardiol Rev."},{"key":"R21-20260506","article-title":"Bridging cardiorenal and hepatic disease: the emerging role of SGLT2 inhibitors in cirrhosis [published online ahead of print December 10, 2025].","author":"Alkasabrah","journal-title":"Cardiol Rev."},{"key":"R22-20260506","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2020.06.005","article-title":"Venous thromboembolic events in inflammatory bowel diseases: a review of current evidence and guidance on risk in the post-hospitalization setting.","volume":"194","author":"Murthy","year":"2020","journal-title":"Thromb Res"},{"key":"R23-20260506","first-page":"93","article-title":"Outcomes of percutaneous coronary intervention in patients with inflammatory bowel disease: a propensity score-matched analysis.","volume":"42","author":"Jain","year":"2026","journal-title":"Can J Cardiol"},{"key":"R24-20260506","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/apt.70162","article-title":"Increased risk of cardiovascular events after coronary interventions in inflammatory bowel disease: a nationwide matched cohort study.","volume":"61","author":"Ebrahimi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-20260506","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11239-015-1315-2","article-title":"Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism.","volume":"41","author":"Smythe","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"R26-20260506","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.3390\/cancers16112082","article-title":"Cancer-associated thrombosis: pathophysiology, laboratory assessment, and current guidelines.","volume":"16","author":"Tsantes","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"Suppl 4","key":"R27-20260506","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0049-3848(09)70137-9","article-title":"Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model.","volume":"123","author":"Sud","year":"2009","journal-title":"Thromb Res"},{"key":"R28-20260506","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism.","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"R29-20260506","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer.","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"R30-20260506","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D).","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"R31-20260506","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1053\/j.gastro.2023.12.020","article-title":"Standard of care versus octreotide in angiodysplasia-related bleeding (the OCEAN study): a multicenter randomized controlled trial.","volume":"166","author":"Goltstein","year":"2024","journal-title":"Gastroenterology"},{"key":"R32-20260506","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"R33-20260506","doi-asserted-by":"crossref","first-page":"899","DOI":"10.14309\/ajg.0000000000001245","article-title":"ACG clinical guideline: upper gastrointestinal and ulcer bleeding.","volume":"116","author":"Laine","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"R37-20260506","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer\u2010associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH.","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"key":"R39-20260506","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism.","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"R40-20260506","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation.","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R41-20260506","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"R42-20260506","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation.","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"R43-20260506","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation.","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"R44-20260506","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"key":"R47-20260506","article-title":"Comprehensive guide to paravalvular leak: symptoms, effects, and treatments [published online ahead of print November 5, 2024].","author":"Agrawal","journal-title":"Cardiol Rev."},{"key":"R48-20260506","article-title":"Management of valvular heart disease in pregnancy: challenges, risk stratification, and multidisciplinary approaches [published online ahead of print March 24, 2025].","author":"Thukral","journal-title":"Cardiol Rev."},{"key":"R49-20260506","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"R50-20260506","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1161\/CIR.0000000000000105","article-title":"2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"130","author":"Fleisher","year":"2014","journal-title":"Circulation"},{"key":"R51-20260506","article-title":"Acute limb ischemia management and complications: from catheter-directed thrombolysis to long-term follow-up [published online ahead of print August 15, 2024].","author":"Maheta","journal-title":"Cardiol Rev."},{"key":"R52-20260506","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014renewing consensus in portal hypertension.","volume":"76","author":"De Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"R53-20260506","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"R54-20260506","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis.","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"R55-20260506","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors.","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"R56-20260506","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.thromres.2019.01.020","article-title":"Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis.","volume":"175","author":"Little","year":"2019","journal-title":"Thromb Res"},{"key":"R57-20260506","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"R58-20260506","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"R59-20260506","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R60-20260506","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jtha.2024.07.009","article-title":"Reversal of direct oral anticoagulants: guidance from the SSC of the ISTH.","volume":"22","author":"Levy","year":"2024","journal-title":"J Thromb Haemost"},{"key":"R61-20260506","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"issue":"1S Suppl 1","key":"R62-20260506","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/MEG.0000000000002035","article-title":"Major gastrointestinal bleeding risk with direct oral anticoagulants: does type and dose matter? A systematic review and network meta-analysis.","volume":"33","author":"Radadiya","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R63-20260506","doi-asserted-by":"crossref","first-page":"102192","DOI":"10.1016\/j.rpth.2023.102192","article-title":"Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.","volume":"7","author":"Dobesh","year":"2023","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:00:46Z","timestamp":1778040046000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":57,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001301","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}